Patents by Inventor Steven Thomas Dock

Steven Thomas Dock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240239861
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Application
    Filed: October 19, 2023
    Publication date: July 18, 2024
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Patent number: 11840559
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: December 12, 2023
    Assignee: i2o Therapeutics, Inc.
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Publication number: 20220332781
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Application
    Filed: November 30, 2021
    Publication date: October 20, 2022
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Patent number: 11214607
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: January 4, 2022
    Assignee: Intarcia Therapeutics Inc.
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Publication number: 20200299350
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Application
    Filed: October 29, 2019
    Publication date: September 24, 2020
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Patent number: 10501517
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: December 10, 2019
    Assignee: INTARCIA THERAPEUTICS, INC.
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Patent number: 9441023
    Abstract: The present invention relates to novel analogs of PYY that have an improved therapeutic profile when compared to native human PYY. These novel PYY analogs are useful in the treatment of obesity, diabetes, and other disorders.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: September 13, 2016
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Steven Thomas Dock, Andrew James Carpenter, Robert Neil Hunter, III, Yulin Wu, Ved P. Srivastava
  • Publication number: 20160108098
    Abstract: The present invention relates to novel analogs of PYY that have an improved therapeutic profile when compared to native human PYY. These novel PYY analogs are useful in the treatment of obesity, diabetes, and other disorders.
    Type: Application
    Filed: April 30, 2014
    Publication date: April 21, 2016
    Inventors: Steven Thomas DOCK, Yulin WU, Ved P Srivastava, Robert Neil HUNTER, III, Andrew James CARPENTER
  • Publication number: 20140329742
    Abstract: The present invention relates to novel analogs of PYY that have an improved therapeutic profile when compared to native human PYY. These novel PYY analogs are useful in the treatment of obesity, diabetes, and other disorders.
    Type: Application
    Filed: April 30, 2014
    Publication date: November 6, 2014
    Applicant: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Steven Thomas Dock, Andrew James Carpenter, Robert Neil Hunter, III, Yulin Wu, Ved P. Srivastava